Blueprint vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical measurement and therapy outcomes platform for mental health providers, Austin TX, raised $8M+. Automates outcome tracking and progress notes for therapists.
About
Blueprint is an Austin, Texas-based clinical technology company founded in 2018 that provides mental health providers with a measurement-based care platform designed to automate outcomes tracking, streamline progress note documentation, and improve the quality and consistency of mental health treatment. The company has raised over $8 million and serves thousands of therapists and group practices seeking to implement structured clinical measurement without significant workflow disruption.\n\nBlueprint's platform automates the collection of validated clinical questionnaires (such as PHQ-9, GAD-7, and PCL-5) before or between sessions, presents clinicians with outcome trend visualizations at the point of care, and generates draft progress notes based on session data. The AI-assisted note generation feature is particularly valued by clinicians who spend significant time on documentation after sessions, with Blueprint reducing note completion time while improving clinical documentation quality and compliance.\n\nThe company distributes through direct sales to individual therapists and group practices, and is expanding partnerships with group practice management platforms and EHR vendors to embed its measurement capabilities into existing clinical workflows. Blueprint competes with Greenspace Health and Osmind in the measurement-based care space, and with Nabla and Heidi Health in the AI-assisted clinical documentation market. The intersection of outcomes accountability and administrative relief positions Blueprint as both a quality improvement tool and a therapist burnout reduction solution.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.